3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
13
Active not recruiting
8
Terminated
6
Recruiting
5
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Large B-Cell, Diffuse
24
Lymphoma
11
Lymphoma, Non-Hodgkin
9
Prostatic Neoplasms
8
Lymphoma, T-Cell, Peripheral
8
Lymphoma, Follicular
7
Leukemia
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Multiple Myeloma
5
Neoplasms, Plasma Cell
4
Lymphoma, Mantle-Cell
4
Hodgkin Disease
3
Burkitt Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Myasthenia Gravis
2
Lymphoma, Large-Cell, Immunoblastic
2
Immunoblastic Lymphadenopathy
2
Subcutaneous panniculitis-like T-cell lymphoma
1
Spinal Cord Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Plasmablastic Lymphoma
1
Pituitary Neoplasms
1
Neoplasms, Experimental
1
Neoplasms
1
Neoplasm Metastasis
1
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
1
Neoadjuvant Therapy
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell
1
Interventions
Exercise
18
Drug Therapy
17
pembrolizumab
12
Capecitabine
11
Blood Specimen Collection
11
Surveys and Questionnaires
10
Radiotherapy
10
Dexamethasone
9
Paclitaxel
8
Standard of Care
7
Oxaliplatin
7
Nivolumab
7
Fluorouracil
7
Erlotinib Hydrochloride
7
apatinib
6
Interviews as Topic
6
Gemcitabine
6
Cisplatin
6
Therapeutics
5
Neoadjuvant Therapy
5
Mindfulness-Based Cognitive Therapy
5
Metformin
5
Injections
5
Everolimus
5
Docetaxel
5
Cyclophosphamide
5
Control Groups
5
Bevacizumab
5
sintilimab
4
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasms
×
Prednisone
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled